Overview

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Met

Status:
Recruiting

Trial end date:
2026-12-31

Target enrollment:

Participant gender:

Summary

The main purpose of the study is to evaluate the safety of GDC-1971 in combination with either osimertinib or cetuximab. The study consists of a dose-finding stage followed by an expansion stage.

Phase:

Phase 1

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Cetuximab
Osimertinib